Teva Confirms Plans To Hive Off API Unit As 2024 Guidance Is Pushed Up Again
Israeli Firm Swings To Q3 Operating Loss Due To Goodwill Charge, Legal Contingencies
A significant divestment in the works, complex generic launches, a mammoth antitrust fine in Europe – Teva’s Q3 was busy and bustling, led by strong, double-digit top-line growth and a further rise in guidance for 2024.
